Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion
Sebastian P. Gnosa, Laia Puig Blasco, Krzysztof B. Piotrowski, Marie L. Freiberg, Simonas Savickas, Daniel H. Madsen, Ulrich auf dem Keller, Pauliina Kronqvist, Marie Kveiborg
Sebastian P. Gnosa, Laia Puig Blasco, Krzysztof B. Piotrowski, Marie L. Freiberg, Simonas Savickas, Daniel H. Madsen, Ulrich auf dem Keller, Pauliina Kronqvist, Marie Kveiborg
View: Text | PDF
Research Article Oncology

ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion

  • Text
  • PDF
Abstract

Macrophages in the tumor microenvironment have a substantial impact on tumor progression. Depending on the signaling environment in the tumor, macrophages can either support or constrain tumor progression. It is therefore of therapeutic interest to identify the tumor-derived factors that control macrophage education. With this aim, we correlated the expression of A Disintegrin and Metalloproteinase (ADAM) proteases, which are key mediators of cell-cell signaling, to the expression of protumorigenic macrophage markers in human cancer cohorts. We identified ADAM17, a sheddase upregulated in many cancer types, as a protein of interest. Depletion of ADAM17 in cancer cell lines reduced the expression of several protumorigenic markers in neighboring macrophages in vitro as well as in mouse models. Moreover, ADAM17–/– educated macrophages demonstrated a reduced ability to induce cancer cell invasion. Using mass spectrometry–based proteomics and ELISA, we identified heparin-binding EGF (HB-EGF) and amphiregulin, shed by ADAM17 in the cancer cells, as the implicated molecular mediators of macrophage education. Additionally, RNA-Seq and ELISA experiments revealed that ADAM17-dependent HB-EGF ligand release induced the expression and secretion of CXCL chemokines in macrophages, which in turn stimulated cancer cell invasion. In conclusion, we provide evidence that ADAM17 mediates a paracrine EGFR-ligand-chemokine feedback loop, whereby cancer cells hijack macrophages to promote tumor progression.

Authors

Sebastian P. Gnosa, Laia Puig Blasco, Krzysztof B. Piotrowski, Marie L. Freiberg, Simonas Savickas, Daniel H. Madsen, Ulrich auf dem Keller, Pauliina Kronqvist, Marie Kveiborg

×

Figure 5

ADAM17-mediated EGFR ligand shedding promotes macrophage-induced cancer cell invasion.

Options: View larger image (or click on image) Download as PowerPoint
ADAM17-mediated EGFR ligand shedding promotes macrophage-induced cancer ...
(A) Experimental setup for qRT-PCR of BMDMs treated with solvent (NC); recombinant CSF-1 (rCSF-1), HB-EGF (rHB-EGF), or amphiregulin (rAREG); or the combination of rCSF-1 and rHB-EGF or rAREG. (B) Relative CD163 and CD206 expression in BMDMs treated with NC, rCSF-1, rHB-EGF, rAREG, or the combination of rCSF-1 and rHB-EGF or rAREG (n = 3). (C) Experimental setup for Boyden chamber invasion assays of WT cancer cells together with BMDMs treated with rCSF-1, rCSF-1+rHB-EGF, or rCSF-1+rAREG. (D) Relative invasion of E0771 cells together with BMDMs treated with rCSF-1, rCSF-1+rHB-EGF, or rCSF-1+rAREG (n = 4). (E) Experimental setup for Boyden chamber invasion assays of WT cancer cells with BMDMs. BMDMs were cocultured with WT cancer cells transfected with nontargeting control (NC), HB-EGF, or AREG siRNA. (F) Relative number of invaded cells/field of WT 4T1 (top) and E0771 (bottom) cells alone or with BMDMs educated with NC, HB-EGF, or AREG siRNA–treated 4T1 or E0771 cells (n = 4). (G) Experimental setup for Boyden chamber invasion assays of WT cancer cells with BMDMs. BMDMs were cocultured with Adam17–/– (A17–/–) cancer cells with or without rHB-EGF or rAREG. (H) Relative invasion of 4T1 and E0771 cells with BMDMs educated by coculture with Adam17–/– cells in NC-, rHB-EGF–, or rAREG-containing medium (n = 3). Mean and standard deviation indicated. Data in B, F, D, and H were analyzed by Kruskal-Wallis with Dunn’s multiple comparison test, *P ≤ 0.05, **P ≤ 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts